Tevogen Bio Holdings Inc. Earnings Per Share Disclosure
| Year ended | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Net loss | $ | (26,275,432 | ) | $ | (13,727,380 | ) | ||
| Series A cumulative preferred stock dividend | (100,000 | ) | (76,712 | ) | ||||
| Series B stock repurchase | 3,613,000 | |||||||
| Series C cumulative preferred stock dividend | (450,000 | ) | (82,603 | ) | ||||
| Net loss attributable to common stockholders | $ | (26,825,432 | ) | $ | (10,273,695 | ) | ||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Outstanding RSUs (a) | 54,110 | 172,465 | ||||||
| Restricted Stock | 571,979 | 386,979 | ||||||
| Warrants | 359,500 | 359,500 | ||||||
| Earnout Shares | 490,000 | 490,000 | ||||||
| Total | 1,475,589 | 1,408,944 | ||||||
| (a) | As of December 31, 2025 there were an additional RSUs that had vested but had not been legally settled into common stock and therefore were included in the basic net income per share. See Note 11 for additional information. |
The above table excludes any potentially anti-dilutive shares as a result of the $ million Purchase Option and the Additional Amount Purchase Option (see Note 8). These are excluded as the number of shares issuable cannot be determined until the conditions for issuance are met and the share prices are known upon exercise.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 31, 2026 | Showing above |
| 2024 | Apr 2, 2025 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.